Table 3.

Multivariate analyses to predict significant prostate cancer in the (a, b) overall population, and (c) in the subset with a PSA <4 ng/ml and biopsy Gleason score of 6.

(a)
	OR (95% CI)	p-value
Age decade	1.04 (0.99-1.07)	0.07
Clinical stage	1.0 (0.6-1.9)	0.93
Biopsy Gleason score	8.9 (2.2-36.7)	0.003
PSAV >0.4 ng/ml/year	1.8 (1.1-3.0)	0.02
(b)
	OR (95% CI)	p-value
Age decade	1.04 (0.99-1.08)	0.07
Clinical stage	1.5 (0.8-3.0)	0.20
Gleason score	7.0 (1.7-28.9)	0.007
PSA	1.4 (1.2-1.6)	0.0002
PSAV >0.4 ng/ml/year	1.4 (0.8-2.4)	0.18
(c)
	OR (95% CI)	p-value
Age decade	1.06 (1.01-1.11)	0.02
Clinical stage	1.3 (0.6-2.7)	0.55
PSAV >0.4 ng/ml/year	2.1 (1.1-4.1)	0.03